NONOF
Price
$78.60
Change
-$3.85 (-4.67%)
Updated
Jan 17 closing price
Capitalization
368.92B
VRTX
Price
$422.00
Change
+$5.04 (+1.21%)
Updated
Jan 17 closing price
Capitalization
108.68B
24 days until earnings call
Ad is loading...

NONOF vs VRTX

Header iconNONOF vs VRTX Comparison
Open Charts NONOF vs VRTXBanner chart's image
Novo-Nordisk A/S
Price$78.60
Change-$3.85 (-4.67%)
Volume$7.08K
Capitalization368.92B
Vertex Pharmaceuticals
Price$422.00
Change+$5.04 (+1.21%)
Volume$1.77M
Capitalization108.68B
NONOF vs VRTX Comparison Chart
Loading...
NONOF
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
VRTX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
NONOF vs. VRTX commentary
Jan 18, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is NONOF is a Hold and VRTX is a Hold.

Ad is loading...
COMPARISON
Comparison
Jan 18, 2025
Stock price -- (NONOF: $78.60 vs. VRTX: $422.00)
Brand notoriety: NONOF and VRTX are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: NONOF: 15% vs. VRTX: 102%
Market capitalization -- NONOF: $368.92B vs. VRTX: $108.68B
NONOF [@Biotechnology] is valued at $368.92B. VRTX’s [@Biotechnology] market capitalization is $108.68B. The market cap for tickers in the [@Biotechnology] industry ranges from $368.92B to $0. The average market capitalization across the [@Biotechnology] industry is $2.37B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

NONOF’s FA Score shows that 2 FA rating(s) are green whileVRTX’s FA Score has 1 green FA rating(s).

  • NONOF’s FA Score: 2 green, 3 red.
  • VRTX’s FA Score: 1 green, 4 red.
According to our system of comparison, NONOF is a better buy in the long-term than VRTX.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

NONOF’s TA Score shows that 5 TA indicator(s) are bullish while VRTX’s TA Score has 4 bullish TA indicator(s).

  • NONOF’s TA Score: 5 bullish, 2 bearish.
  • VRTX’s TA Score: 4 bullish, 3 bearish.
According to our system of comparison, NONOF is a better buy in the short-term than VRTX.

Price Growth

NONOF (@Biotechnology) experienced а -8.39% price change this week, while VRTX (@Biotechnology) price change was +3.04% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -1.44%. For the same industry, the average monthly price growth was +2.66%, and the average quarterly price growth was -1.92%.

Reported Earning Dates

VRTX is expected to report earnings on Apr 30, 2025.

Industries' Descriptions

@Biotechnology (-1.44% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
NONOF($369B) has a higher market cap than VRTX($109B). VRTX has higher P/E ratio than NONOF: VRTX (32.76) vs NONOF (26.85). VRTX YTD gains are higher at: 4.793 vs. NONOF (-8.495). NONOF has higher annual earnings (EBITDA): 136B vs. VRTX (518M). NONOF has more cash in the bank: 74.9B vs. VRTX (6.52B). VRTX has less debt than NONOF: VRTX (1.7B) vs NONOF (57B). NONOF has higher revenues than VRTX: NONOF (271B) vs VRTX (10.6B).
NONOFVRTXNONOF / VRTX
Capitalization369B109B339%
EBITDA136B518M26,255%
Gain YTD-8.4954.793-177%
P/E Ratio26.8532.7682%
Revenue271B10.6B2,557%
Total Cash74.9B6.52B1,148%
Total Debt57B1.7B3,347%
FUNDAMENTALS RATINGS
NONOF vs VRTX: Fundamental Ratings
NONOF
VRTX
OUTLOOK RATING
1..100
8319
VALUATION
overvalued / fair valued / undervalued
1..100
31
Undervalued
77
Overvalued
PROFIT vs RISK RATING
1..100
4418
SMR RATING
1..100
1390
PRICE GROWTH RATING
1..100
9163
P/E GROWTH RATING
1..100
9336
SEASONALITY SCORE
1..100
50n/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

NONOF's Valuation (31) in the null industry is somewhat better than the same rating for VRTX (77) in the Biotechnology industry. This means that NONOF’s stock grew somewhat faster than VRTX’s over the last 12 months.

VRTX's Profit vs Risk Rating (18) in the Biotechnology industry is in the same range as NONOF (44) in the null industry. This means that VRTX’s stock grew similarly to NONOF’s over the last 12 months.

NONOF's SMR Rating (13) in the null industry is significantly better than the same rating for VRTX (90) in the Biotechnology industry. This means that NONOF’s stock grew significantly faster than VRTX’s over the last 12 months.

VRTX's Price Growth Rating (63) in the Biotechnology industry is in the same range as NONOF (91) in the null industry. This means that VRTX’s stock grew similarly to NONOF’s over the last 12 months.

VRTX's P/E Growth Rating (36) in the Biotechnology industry is somewhat better than the same rating for NONOF (93) in the null industry. This means that VRTX’s stock grew somewhat faster than NONOF’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
NONOFVRTX
RSI
ODDS (%)
Bullish Trend 11 days ago
90%
Bullish Trend 11 days ago
71%
Stochastic
ODDS (%)
Bullish Trend 11 days ago
79%
Bearish Trend 11 days ago
66%
Momentum
ODDS (%)
N/A
Bullish Trend 11 days ago
63%
MACD
ODDS (%)
Bearish Trend 11 days ago
65%
Bullish Trend 11 days ago
53%
TrendWeek
ODDS (%)
Bearish Trend 11 days ago
61%
Bullish Trend 11 days ago
59%
TrendMonth
ODDS (%)
Bearish Trend 11 days ago
66%
Bearish Trend 11 days ago
43%
Advances
ODDS (%)
Bullish Trend 16 days ago
75%
Bullish Trend 11 days ago
61%
Declines
ODDS (%)
Bearish Trend 12 days ago
57%
Bearish Trend 20 days ago
44%
BollingerBands
ODDS (%)
Bullish Trend 11 days ago
81%
N/A
Aroon
ODDS (%)
Bullish Trend 11 days ago
69%
Bearish Trend 11 days ago
37%
View a ticker or compare two or three
Ad is loading...
NONOF
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
VRTX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
BCS14.260.27
+1.93%
Barclays PLC
PFSI107.620.97
+0.91%
PennyMac Financial Services
FNLC26.14-0.01
-0.04%
First Bancorp
KIRK1.57-0.01
-0.63%
Kirkland's
AGRO9.66-0.19
-1.93%
Adecoagro SA

NONOF and

Correlation & Price change

A.I.dvisor indicates that over the last year, NONOF has been closely correlated with NVO. These tickers have moved in lockstep 70% of the time. This A.I.-generated data suggests there is a high statistical probability that if NONOF jumps, then NVO could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To NONOF
1D Price
Change %
NONOF100%
-4.67%
NVO - NONOF
70%
Closely correlated
-5.27%
LABFF - NONOF
23%
Poorly correlated
N/A
IMRN - NONOF
22%
Poorly correlated
+8.59%
QSI - NONOF
21%
Poorly correlated
-11.81%
VRTX - NONOF
21%
Poorly correlated
+1.21%
More